Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 13NIH 10NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Recurrent Squamous Cell Lung Carcinoma 3Colorectal Neoplasms 2Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Fallopian Tube Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Paclitaxel 15Carboplatin 15Taxes 9Cisplatin 8Topotecan 4Docetaxel 4Filgrastim 3pegfilgrastim 2paclitaxel poliglumex 2liposomal doxorubicin 2Methods 2Gemcitabine 2GEN-1 2Etoposide 2Erlotinib Hydrochloride 2Educational Status 2Early Intervention, Educational 2Chemotherapy, Adjuvant 2vandetanib 1rilotumumab 1oregovomab 1motesanib diphosphate 1elesclomol 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Watchful Waiting 1VTX-2337 1Trabectedin 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Fallopian Tube Neoplasms × Immunoglobulin G × Clear all
NCT00886691 2022-02-04

Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

GOG Foundation

Phase 2 Completed
150 enrolled 11 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡